查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1950489

膝下動脈支架市場（按產品、手術、適應症、植入位置、最終用戶和分銷管道分類），全球預測，2026-2032年

Infrapopliteal Artery Stent Market by Product, Procedure, Indication, Implant Location, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，腿部動脈支架市場價值將達到 20.2 億美元，到 2026 年將成長至 22 億美元，到 2032 年將達到 41.5 億美元，年複合成長率為 10.83%。

關鍵市場統計數據
基準年 2025 20.2億美元
預計年份：2026年 22億美元
預測年份 2032 41.5億美元
複合年成長率 (%) 10.83%

下膝動脈支架環境簡明框架：重點關注臨床需求、供應考慮和不斷變化的醫療機構採用趨勢

小腿動脈支架在現代下肢周邊動脈疾病的治療中發揮核心作用，特別適用於涉及脛動脈和腓動脈床的病變。近年來，支架設計和藥物傳遞技術的臨床進展重塑了手術決策，使介入團隊能夠應對複雜的解剖結構，並在保肢的同時降低血管再阻塞的風險。因此，臨床醫生和醫療系統越來越傾向於從病變特徵、患者合併症以及預期長期通暢率等綜合觀點來評估器械的選擇。

材料創新、藥物釋放型技術的進步以及手術流程的改變如何重塑下肢血管介入治療中的器械選擇和臨床路徑

膝下動脈支架植入術領域正經歷變革性的轉變，材料科學的創新、先進的藥物釋放型技術以及不斷改進的手術流程正在重塑臨床決策。生物可吸收支架設計和聚合物工程的最新進展，有助於在維持短期血管完整性的同時，減少慢性異物反應，促使介入醫師採用更精細的選擇標準。同時，覆膜支架結構和密封技術的進步，正在改善複雜病變亞組的治療效果，並促使人們在病變形態或血流（流向周邊血管的血流）需要特殊解決方案時，考慮針對特定器械的適應症。

評估2025年美國關稅對採購、價格談判和供應韌性的營運和策略影響

2025年美國關稅調整對膝下支架供應鏈中的製造商、經銷商和醫療器材採購商產生了複雜的營運和戰略影響。某些進口醫療設備組件關稅的提高，給依賴跨境採購特種合金、聚合物和藥物釋放型化合物的製造商帶來了到岸成本上行壓力。為此，供應鏈管理人員立即重新評估了供應商組合，盡可能優先考慮區域採購，並加快供應商資格認證流程，以確保在關稅波動期間生產的連續性。

將下肢動脈領域的器械選擇和商業化策略與按產品類型、臨床環境和手術階段分類的詳細細分分析聯繫起來

一個完善的細分框架闡明了產品類型、最終用戶、分銷管道、手術分類、臨床適應症和植入部位如何各自對臨床應用和商業策略產生不同的影響。產品細分比較了裸金屬支架、生物可吸收支架、覆膜支架和藥物釋放型支架，並指出藥物釋放型技術進一步細分為生物可吸收和永久性聚合物兩種類型，每種類型對發炎反應、藥物遞送動力學和臨床醫生偏好的影響各不相同。最終用戶細分突顯了門診手術中心、醫院和專科診所在採購趨勢和臨床工作流程方面的差異，這些機構的病例組合、醫療設備庫存政策和庫存管理實踐都存在顯著差異。

美洲、歐洲、中東和非洲以及亞太地區的區域性因素將決定監管應對措施、推廣速度和商業化策略。

區域趨勢對監管路徑、報銷機制和臨床偏好產生了重大影響，進而影響著膝下支架技術在不同醫療體系中的引入和推廣。在美洲，臨床醫師對血管內手術的熟悉程度以及醫院成熟的採購機制，往往有利於快速採用漸進式器械創新。然而，支付方和醫療體系越來越需要與臨床結果和總醫療成本相關的可靠價值證明。因此，希望在該地區實現商業化的製造商高度重視真實世界數據（RWE）的生成、上市後監測以及與主要醫療體系達成按績效付費協議。

創新通路、實證項目和市場推廣模式塑造了支架器材公司的競爭差異化和長期商業性永續性。

膝下支架領域的競爭日益激烈，其促進因素包括差異化的技術組合、已證實的臨床證據以及為臨床醫生和醫療系統提供整合服務的能力。大型器械開發商投資於下一代藥物釋放型化學、聚合物科學和低輪廓輸送系統，使其能夠應對複雜的脛腓骨解剖結構；而規模較小的創新者則專注於塗層治療和生物可吸收支架等細分應用，以滿足特定的血管再阻塞和閉合需求。除了器械性能外，能夠透過結構化的臨床計畫和註冊研究證明可重複的手術結果的公司，更有可能贏得臨床醫生的信任和醫療機構的廣泛採用。

以行動為導向的策略重點，將臨床證據產生、供應鏈韌性和區域商業化連結起來，以加速永續的醫療器材普及應用。

為了在膝下護理領域實現持續價值，產業領導者應優先考慮協作策略，將產品創新與臨床醫生的需求、營運實際情況和支付方的期望相結合。這首先需要投資於有針對性的臨床項目，以產生與手術特異性的證據，從而將器械屬性與有意義的患者預後聯繫起來。應著重於註冊研究和務實的試驗設計，並輔以隨機對照試驗數據。這些證據必須轉化為清晰的價值提案，供醫院採購團隊和門診服務提供者參考，重點在於闡述器械選擇如何影響手術效率、再次手術率和病患復健路徑。

嚴謹的多源調查方法，結合臨床文獻綜述、監管分析以及與關鍵相關人員的面對面訪談，確保了研究結果的平衡性和可操作性。

本研究採用多方面方法，整合了同行評審的臨床文獻、監管文件、醫療設備附加檔以及對臨床醫生、供應鏈專家和商業領袖的訪談，以全面了解技術、臨床和市場動態。研究評估了臨床證據，包括研究設計品質、患者族群特徵、病變特異性結局和追蹤期，以確定研究結果對常見膕窩下適應症的適用性。此外，研究還審查了監管路徑和核准情況，以了解市場進入要求並識別不同司法管轄區上市後警戒期望的差異。

整合設備創新、臨床應用因素和營運要求，為下肢動脈疾病治療的進展制定切實可行的方案

總而言之，膝下支架領域呈現出多種因素交會融合的特徵：器械創新、手術流程演進和商業性整合，這些因素共同塑造著臨床醫生和醫療系統進行下肢重組的方式。藥物釋放型化學、聚合物技術和支架設計的進步拓展了治療選擇，但不斷變化的醫療環境和日益成長的採購壓力要求製造商提供清晰的臨床益處、物流可行性和經濟價值的證據。 2025年關稅帶來的衝擊進一步凸顯了供應鏈彈性和透明成本模型對於維持治療可近性和可負擔性的重要性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 膝下動脈支架市場（依產品分類）

  • 裸金屬支架
  • 生物可吸收支架
  • 覆膜支架
  • 藥物釋放型支架
    • 生物可吸收聚合物
    • 永久聚合物

9. 依手術方式分類的膝下動脈支架市場

  • 首次植入
  • 血管再阻塞管理
    • 新病變
    • 支架內血管再阻塞

第10章 依適應症分類的膝下動脈支架市場

  • 嚴重肢體缺血
  • 間歇性跛行

第11章 依植入部位分類的膝下動脈支架市場

  • 脛前動脈
  • 腓動脈
  • 脛後動脈

第12章 膝下動脈支架市場（依最終用戶分類）

  • 門診手術中心
  • 醫院
  • 專科診所

第13章 膝下動脈支架市場（依通路分類）

  • 直接競標
  • 經銷商
  • 線上管道

第14章 膝下動脈支架市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 膝下動脈支架市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國膝下動脈支架市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

17. 美國膝下支架市場

第18章：中國膝下動脈支架市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • CR Bard, Inc.
  • Cardiovascular Systems, Inc.
  • Cook Medical, Inc.
  • Cordis LLC
  • Endologix, Inc.
  • Gore Medical
  • iVascular SLU
  • Jotec GmbH
  • Lombard Medical Technologies
  • Medtronic plc
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • Synectic Medical Limited
  • Teleflex Incorporated
  • Terumo Corporation
  • Translumina GmbH
  • WL Gore & Associates, Inc.
Product Code: MRR-4F7A6D4FD898

The Infrapopliteal Artery Stent Market was valued at USD 2.02 billion in 2025 and is projected to grow to USD 2.20 billion in 2026, with a CAGR of 10.83%, reaching USD 4.15 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.02 billion
Estimated Year [2026] USD 2.20 billion
Forecast Year [2032] USD 4.15 billion
CAGR (%) 10.83%

Concise framing of the infrapopliteal stent environment highlighting clinical imperatives, supply considerations, and evolving provider adoption dynamics

Infrapopliteal artery stents are central to contemporary management of peripheral arterial disease affecting the lower extremities, particularly when lesions involve the tibial and peroneal vascular beds. Recent clinical advances in stent design and drug delivery have reshaped procedural decision making, enabling interventional teams to address complex anatomies and mitigate restenosis risk while balancing limb salvage objectives. As a result, clinicians and health systems increasingly evaluate device selection through a lens that integrates lesion characteristics, patient comorbidity profiles, and expected long-term patency outcomes.

Beyond clinical performance, the landscape is influenced by supply chain resilience, vendor service models, and the evolving reimbursement environment which together affect hospital purchasing pathways and ambulatory care adoption. Transitional shifts in outpatient procedural settings and the growing emphasis on clinician-led value demonstrations require manufacturers to align evidence generation with real-world utilization patterns. Consequently, stakeholders must synthesize clinical evidence, operational feasibility, and regulatory constraints to craft strategies that support both improved patient outcomes and sustainable commercial performance.

This introduction frames the subsequent analysis by clarifying the key levers-technology innovation, clinical pathways, and commercial dynamics-that are driving choices at institutional and provider levels when treating infrapopliteal disease.

How material innovation, drug-elution advances, and procedural shifts are reshaping device selection and clinical pathways for lower limb vascular interventions

The infrapopliteal stent arena is experiencing transformative shifts driven by material science innovations, refined drug-elution technologies, and procedural workflow evolution that collectively reconfigure clinical decision making. Recent developments in bioresorbable scaffold design and polymer engineering have opened pathways to reduce chronic foreign-body responses while maintaining short-term vessel scaffolding, and consequently have prompted more nuanced selection criteria among interventionalists. At the same time, advances in covered stent construction and the refinement of sealing technologies have improved outcomes in complex lesion subsets, encouraging consideration of device-specific applications where lesion morphology and runoff demand targeted solutions.

Parallel to device innovation, procedural shifts toward ambulatory and hybrid care models are influencing how providers prioritize device profiles that enable rapid recovery and low complication rates. These delivery-model changes reinforce the need for manufacturers to demonstrate not only clinical efficacy but also economic and logistical compatibility with outpatient workflows. Moreover, the acceleration of digital health tools and imaging integration facilitates more precise lesion assessment and tailored stent deployment, thereby enhancing procedural predictability. Taken together, these trends are redefining value propositions and prompting stakeholders to re-evaluate clinical pathways, evidence strategies, and commercialization approaches to remain competitive.

Assessing the operational and strategic reverberations of the United States tariff measures in 2025 that influenced sourcing, pricing negotiations, and supply resilience

Tariff adjustments implemented in 2025 by the United States introduced a complex layer of operational and strategic implications for manufacturers, distributors, and healthcare purchasers involved in infrapopliteal stent supply chains. Increased duties on certain imported medical device components created upward pressure on landed costs for manufacturers reliant on cross-border sourcing of specialized alloys, polymers, and drug-eluting compounds. As an immediate response, supply-chain managers reassessed vendor portfolios, prioritized regional sourcing where feasible, and accelerated supplier qualification processes to insulate production continuity from tariff volatility.

In addition, the tariffs prompted pricing discussions between vendors and institutional purchasers, with contract renegotiations increasingly referencing total landed cost and service-level guarantees. For some manufacturers, the tariffs stimulated investments in localized manufacturing capacity to reduce exposure to import duties and to expedite time-to-market for iterative device improvements. From a downstream perspective, hospitals and ambulatory centers engaged more actively with procurement partners to understand the net impact on contract value and device availability, paying particular attention to the interplay between device cost, reimbursement pathways, and clinical outcomes. Overall, the cumulative effect of the 2025 tariffs reinforced the importance of flexible sourcing, transparent cost modeling, and collaborative commercial agreements to preserve access and manage cost pressures across the care continuum.

Granular segmentation insights linking product types, care settings, and procedural distinctions to device selection and commercialization strategies across infrapopliteal applications

A robust segmentation framework clarifies how product types, end users, distribution channels, procedural classifications, clinical indications, and implant locations each exert distinct influences on clinical adoption and commercial strategy. Product segmentation contrasts bare metal stents, bioresorbable scaffolds, covered stents, and drug-eluting stents, and recognizes that drug-eluting technologies further bifurcate into bioabsorbable polymer and permanent polymer approaches, each with distinct implications for inflammatory response, drug delivery kinetics, and clinician preference. End-user segmentation highlights differences in procurement dynamics and clinical workflows across ambulatory surgical centers, hospitals, and specialty clinics, where case mix, device stocking policies, and inventory management practices vary substantially.

Distribution channel distinctions between direct tender, distributor networks, and online channels affect turnaround times, contractual complexity, and service provision, while procedure-based segmentation between primary implantation and restenosis management-where restenosis management itself separates into de novo lesion treatment and in-stent restenosis modalities-shapes device selection criteria tied to lesion history and vessel biology. Indication-driven segmentation separating critical limb ischemia from intermittent claudication underscores divergent clinical priorities, with limb salvage imperatives often elevating the importance of long-term patency and reintervention risks. Finally, implant-location segmentation across anterior tibial, peroneal, and posterior tibial arteries draws attention to device profile, flexibility, and deliverability requirements driven by vessel calibre and tortuosity. Collectively, this layered segmentation supports systematic alignment of product development, evidence generation, and go-to-market tactics that map to distinct clinical and purchasing realities.

Regional considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory navigation, adoption pacing, and commercialization approaches

Regional dynamics materially influence regulatory pathways, reimbursement practices, and clinical preferences, shaping how infrapopliteal stent technologies are introduced and scaled across different healthcare systems. In the Americas, clinician familiarity with endovascular approaches and established hospital procurement mechanisms often facilitate rapid adoption of incremental device innovations, yet payers and health systems increasingly require robust value demonstration tied to clinical outcomes and total cost of care. Consequently, manufacturers pursuing commercialization in this region emphasize real-world evidence generation, post-market surveillance, and collaborative outcome-based agreements with major health systems.

Across Europe, Middle East & Africa, regulatory harmonization efforts and diverse reimbursement landscapes create both opportunities and complexities for device manufacturers. European centers of excellence tend to adopt evidence-driven innovations where clinical guidance and multicenter data support practice change, while in the Middle East and Africa device access and adoption hinge on local procurement policies and programmatic investments in vascular services. By contrast, Asia-Pacific presents a heterogeneous set of adoption pathways influenced by strong domestic manufacturing capabilities in several markets, differing regulatory timelines, and a growing emphasis on cost-effectiveness in public procurement. Transitioning between regions, manufacturers must adapt regulatory strategies, clinical engagement models, and distribution frameworks to reflect local payer expectations, procedural norms, and infrastructure capabilities.

How innovation pipelines, evidence programs, and go-to-market models shape competitive differentiation and long-term commercial resilience in stent device companies

Competitive intensity in the infrapopliteal stent sector is driven by differentiated technology portfolios, evidence credentials, and the ability to deliver integrated services that support clinicians and health systems. Leading device developers that invest in next-generation drug-elution chemistry, polymer science, and low-profile delivery systems position themselves to address complex tibial and peroneal anatomies, while smaller innovators focus on niche applications such as covered therapies or bioresorbable scaffolds that address specific restenosis or sealing requirements. Beyond device performance, companies that can demonstrate reproducible procedural outcomes through structured clinical programs and registries tend to achieve stronger clinician trust and institutional adoption.

Moreover, channel strategies and commercial support models-ranging from direct tender engagement with large hospital systems to distributor-managed inventories and expanding online procurement platforms-shape competitive advantage. Firms that integrate training programs, procedural simulation, and localized clinical support reduce adoption friction and create durable clinical partnerships. Finally, strategic collaborations between device developers, contract manufacturers, and logistics providers help mitigate supply-chain risks and support scalable deployments across varied care settings. These competitive dynamics encourage continuous investment in clinical evidence, operational excellence, and differentiated service offerings to sustain long-term relevance in the marketplace.

Action-oriented strategic priorities that align clinical evidence generation, supply resilience, and localized commercialization to accelerate sustainable device adoption

Industry leaders should prioritize a coordinated strategy that aligns product innovation with clinician needs, operational realities, and payer expectations to capture durable value in infrapopliteal interventions. First, invest in targeted clinical programs that generate procedure-specific evidence linking device features to meaningful patient outcomes, with a focus on registries and pragmatic trial designs that complement randomized data. This evidence must then be translated into clear value narratives for hospital procurement teams and ambulatory care providers, emphasizing how device selection affects procedural efficiency, reintervention rates, and patient recovery pathways.

Second, optimize supply-chain flexibility by diversifying component sourcing and evaluating regional manufacturing options to reduce exposure to policy-driven cost fluctuations. Third, tailor commercialization approaches to local care delivery models by deploying differentiated sales and service footprints that support training, inventory management, and outcome monitoring. Fourth, cultivate strategic partnerships with imaging providers, digital health vendors, and reimbursement advisors to create integrated solutions that simplify adoption for clinicians and purchasing stakeholders. Lastly, maintain a disciplined approach to post-market surveillance and iterative product improvement, ensuring that clinical feedback loops inform next-generation design and service enhancements. These coordinated actions will enable organizations to navigate complexity while sustaining clinical credibility and commercial momentum.

Rigorous multi-source methodology combining clinical literature review, regulatory analysis, and primary stakeholder interviews to ensure balanced and actionable insights

This research adopted a multi-method approach combining synthesis of peer-reviewed clinical literature, regulatory documentation, device labeling, and primary interviews with clinicians, supply-chain professionals, and commercial leaders to construct a balanced view of technological, clinical, and market dynamics. Clinical evidence was evaluated for study design quality, patient population characteristics, lesion-specific outcomes, and follow-up duration to determine the applicability of results across common infrapopliteal indications. Regulatory pathways and approvals were reviewed to map market access requirements and to identify emergent differences in post-market surveillance expectations across jurisdictions.

Primary qualitative interviews provided context on procurement practices, clinician device preferences, and procedural workflow constraints, while secondary analysis of public filings and clinical registries helped corroborate adoption drivers and product positioning. Care was taken to triangulate findings across multiple independent sources to mitigate single-source bias, and methodological limitations-such as variation in lesion definitions and heterogeneity in follow-up protocols-were explicitly considered when interpreting comparative device performance. Together, these methods yield a pragmatic, evidence-informed perspective intended to support operational decision making and strategic planning.

Synthesis of device innovation, clinical adoption factors, and operational imperatives that define practical pathways for advancing infrapopliteal patient care

In summary, the infrapopliteal stent landscape is characterized by converging forces of device innovation, procedural evolution, and commercial realignment that together shape how clinicians and health systems approach lower limb revascularization. Advances in drug-elution chemistries, polymer technologies, and scaffold design have expanded therapeutic options, while changing care settings and procurement pressures necessitate that manufacturers provide clear evidence of clinical benefit, logistical compatibility, and economic value. The 2025 tariff-driven disruptions further underscored the need for supply-chain agility and transparent cost modeling to sustain access and affordability.

Looking forward, successful organizations will be those that translate technical differentiation into reproducible clinical outcomes, demonstrate operational alignment with diverse care settings, and engage proactively with payers and providers to articulate compelling value propositions. By integrating targeted evidence generation, resilient sourcing strategies, and localized commercialization plans, stakeholders can better navigate the evolving environment and support improved patient outcomes in peripheral arterial disease management. This conclusion reinforces the practical imperatives for device developers, clinical leaders, and procurement teams as they plan next steps.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Infrapopliteal Artery Stent Market, by Product

  • 8.1. Bare Metal Stent
  • 8.2. Bioresorbable Scaffold
  • 8.3. Covered Stent
  • 8.4. Drug Eluting Stent
    • 8.4.1. Bioabsorbable Polymer
    • 8.4.2. Permanent Polymer

9. Infrapopliteal Artery Stent Market, by Procedure

  • 9.1. Primary Implantation
  • 9.2. Restenosis Management
    • 9.2.1. De Novo Lesion
    • 9.2.2. In-Stent Restenosis

10. Infrapopliteal Artery Stent Market, by Indication

  • 10.1. Critical Limb Ischemia
  • 10.2. Intermittent Claudication

11. Infrapopliteal Artery Stent Market, by Implant Location

  • 11.1. Anterior Tibial Artery
  • 11.2. Peroneal Artery
  • 11.3. Posterior Tibial Artery

12. Infrapopliteal Artery Stent Market, by End User

  • 12.1. Ambulatory Surgical Center
  • 12.2. Hospital
  • 12.3. Specialty Clinic

13. Infrapopliteal Artery Stent Market, by Distribution Channel

  • 13.1. Direct Tender
  • 13.2. Distributor
  • 13.3. Online Channel

14. Infrapopliteal Artery Stent Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Infrapopliteal Artery Stent Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Infrapopliteal Artery Stent Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Infrapopliteal Artery Stent Market

18. China Infrapopliteal Artery Stent Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. B. Braun Melsungen AG
  • 19.7. Becton, Dickinson and Company
  • 19.8. Biotronik SE & Co. KG
  • 19.9. Boston Scientific Corporation
  • 19.10. C.R. Bard, Inc.
  • 19.11. Cardiovascular Systems, Inc.
  • 19.12. Cook Medical, Inc.
  • 19.13. Cordis LLC
  • 19.14. Endologix, Inc.
  • 19.15. Gore Medical
  • 19.16. iVascular S.L.U.
  • 19.17. Jotec GmbH
  • 19.18. Lombard Medical Technologies
  • 19.19. Medtronic plc
  • 19.20. Meril Life Sciences Pvt. Ltd.
  • 19.21. MicroPort Scientific Corporation
  • 19.22. Synectic Medical Limited
  • 19.23. Teleflex Incorporated
  • 19.24. Terumo Corporation
  • 19.25. Translumina GmbH
  • 19.26. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES INFRAPOPLITEAL ARTERY STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY BARE METAL STENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY BARE METAL STENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY BARE METAL STENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY BIORESORBABLE SCAFFOLD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY BIORESORBABLE SCAFFOLD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY BIORESORBABLE SCAFFOLD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COVERED STENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COVERED STENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COVERED STENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PERMANENT POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PERMANENT POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PERMANENT POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRIMARY IMPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRIMARY IMPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRIMARY IMPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DE NOVO LESION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DE NOVO LESION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DE NOVO LESION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IN-STENT RESTENOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IN-STENT RESTENOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IN-STENT RESTENOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY ANTERIOR TIBIAL ARTERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY ANTERIOR TIBIAL ARTERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY ANTERIOR TIBIAL ARTERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PERONEAL ARTERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PERONEAL ARTERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PERONEAL ARTERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY POSTERIOR TIBIAL ARTERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY POSTERIOR TIBIAL ARTERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY POSTERIOR TIBIAL ARTERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY ONLINE CHANNEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY ONLINE CHANNEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY ONLINE CHANNEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. GCC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 158. GCC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 159. GCC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 160. GCC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 161. GCC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. GCC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 163. GCC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. GCC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. G7 INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 185. G7 INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 186. G7 INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 187. G7 INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 188. G7 INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 189. G7 INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 190. G7 INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. G7 INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. NATO INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 194. NATO INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 195. NATO INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 196. NATO INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 197. NATO INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 198. NATO INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 199. NATO INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. NATO INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES INFRAPOPLITEAL ARTERY STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)